The Latest Breaking News from Novartis

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

Novartis stock tumbled Thursday after the firm dropped out of a key cancer treatment race vs. big players Amgen and Bristol Myers Squibb.

Novartis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.

Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.